ALEC enters its May 11 earnings release with options traders showing the most defensive tilt in months — a notable shift for a stock where calls have long dominated the order flow.
The sharpest signal heading into the print is in options positioning. The put/call ratio has climbed to 0.12 — still low in absolute terms, but nearly two standard deviations above its 20-day average of 0.046. That is the most cautious options posture the stock has carried in weeks, and it emerged abruptly: the PCR was running at just 0.028 for most of April before nearly quadrupling in the first week of May. The move follows a rough single session — ALEC fell 5% on May 7 to $2.44 — even as its one-month trend remains modestly positive, up roughly 4%.
Short interest, by contrast, does not tell an aggressive bearish story. It has fallen almost 20% over the past month to 4.4% of the free float. Borrow conditions reinforce the picture: cost to borrow is just 0.50%, essentially at the risk-free rate, and availability in the lending market remains wide. The short score of 46 sits near the middle of the range, down from a brief spike above 51 in late April that quickly faded. Shorts are retreating, not piling in — the hedging demand visible in options is coming from holders, not from new short-sellers.
The bull and bear debate here is ultimately about pipeline credibility. Bulls point to Alector's ABC platform, which has shown 18–32x brain uptake in primates, and to AL101 and AL002 as potential proof-of-concept catalysts in Alzheimer's and Parkinson's disease. The analyst community has been split but recently tilting more constructive: Cantor Fitzgerald upgraded to Overweight in mid-April, and BTIG moved to Buy in March with a $6 target. The consensus mean target of $3.10 implies meaningful upside from current levels. Bears, however, anchor on the INFRONT-3 failure — latozinemab's inability to meet its primary endpoint cast serious doubt on translational biology risk — and note the company carries a net loss approaching $108 million against estimated revenues of just $35 million, sustained by a cash position (net debt is negative at roughly -$284 million, i.e., net cash) that is itself the core asset protecting the thesis.
Institutional ownership adds one layer of interest. TCG Crossover entered with a 10-million-share position as of December, making it the largest outside holder at over 9% of shares. Several other specialist biotech funds — 683 Capital, Balyasny, Foresite — also built or initiated positions in late 2025. Past earnings reactions have been wide: a 14% drop and then a 17% bounce at the two most recent quarterly events, with five-day moves consistently negative even after positive day-one reactions. The May 11 print will test whether the ABC platform's early clinical narrative is strong enough to hold the investor base that assembled around it — or whether another data setback reprises the pattern of short-lived rallies followed by continued erosion.
See the live data behind this article on ORTEX.
Open ALEC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
